EMS State of the Science: A Gathering of Eagles XVIII
This is a brief, encapsulated report by JEMS editor-in-chief A.J. Heightman from the Eagles conference. He recommends that you go to www.gatheringofeagles.us after the conference to download and read the full presentation slides, background, research and recommendations, and that you receive your medical director’s approval before implementing any changes to your protocols and care practices.
Friday, Feb. 19, 2016
Paul E. Pepe, MD, MPH, Eagles Conference course coordinator, opened the 18th annual conference by introducing Dr. Corey Slovis, who was recently awarded th...
Source: JEMS Administration and Leadership - February 19, 2016 Category: Emergency Medicine Authors: A.J. Heightman, MPA, EMT-P Tags: News Administration and Leadership Source Type: news
Oct 9 Cardiology News Oct 9 Cardiology News
Possible aortic-valve thrombosis, coronary calcium, amiodarone, remote ischemic preconditioning, cancer and the heart are topics for this week's podcast with John Mandrola theheart.org on Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 9, 2015 Category: Consumer Health News Tags: Cardiology News Source Type: news
Amiodarone Confers a Small Risk for Optic NeuropathyAmiodarone Confers a Small Risk for Optic Neuropathy
Physicians should monitor visual symptoms in amiodarone users. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 2, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
ED sedation with droperidol is relatively safe and effective
This study has shown that droperidol is relatively safe and effective for the management of violent and aggressive patients in the ED and that there was no increased risk of QT prolongation and torsades de points according to a large cohort of cases.”
The “Editor’s Capsule Summary” that accompanies the article is even more emphatic*:
How this is relevant to clinical practice
Droperidol is safe even with the high doses used in this study.
The authors note that the study does not rule out that droperidol may be associated with rare cases of torsades. But the agitated, delirious ED patient may be a dan...
Source: The Poison Review - May 20, 2015 Category: Toxicology Authors: Leon Tags: Best of TPR Medical black box warning droperidol FDA food and drug administration QT prolongation torsades de pointes Source Type: news
Your NEJM Group Today: Amiodarone & Vortex Keratopathy, Antibiotics & Overweight Toddlers, Connecticut IM Opportunity (FREE)
By the Editors
NEJM Group offers so many valuable resources for practicing clinicians. Here's what we chose for you today: … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 27, 2015 Category: Primary Care Source Type: news
EMA: Heart Risk From Amiodarone Plus Hepatitis C AntiviralsEMA: Heart Risk From Amiodarone Plus Hepatitis C Antivirals
The caution applies to several medications with sofosbuvir, used to fight hepatitis C; the caution in Europe mirrors similar antiviral labeling changes announced by the US FDA within the past month. News Alerts (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - April 24, 2015 Category: Internal Medicine Tags: Cardiology News Alert Source Type: news
EU regulators warn against combining hepatitis C drugs with amiodarone
(Reuters) - European health regulators warned on Friday against using Gilead Sciences Inc's and Bristol-Myers Squibb Co's hepatitis C medicines along with amiodarone, a drug used to regulate the heartbeat of people with heart rhythm disorders. (Source: Reuters: Health)
Source: Reuters: Health - April 24, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
HCV Antiviral Simeprevir Label Warns of Cardiac RiskHCV Antiviral Simeprevir Label Warns of Cardiac Risk
The approved labeling change from the FDA warns of an increased risk of bradycardia with simeprevir when it is used in combination with amiodarone and sofosbuvir. News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 17, 2015 Category: Cardiology Tags: Cardiology News Alert Source Type: news
Could the HCV Drug Sofosbuvir Be Cardiotoxic? Could the HCV Drug Sofosbuvir Be Cardiotoxic?
The FDA warning about a potential interaction between amiodarone and the new HCV drugs Sovaldi/Harvoni prompts Dr John Mandrola to wonder if the problem may lie with the antivirals. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 31, 2015 Category: Cardiology Tags: Cardiology Expert Column Source Type: news
FDA Warns of Cardiac Effect When Heart Drug Mixed With Hepatitis C Meds
Adding Harvoni or Sovaldi to amiodarone could cause dangerous slowing of heart rate, agency says (Source: WebMD Health)
Source: WebMD Health - March 25, 2015 Category: Consumer Health News Source Type: news
FDA Warns of Cardiac Effect When Heart Drug Mixed with Hepatitis C Meds
Adding Harvoni or Sovaldi to amiodarone could cause dangerous slowing of heart rate, agency says
Source: HealthDay
Related MedlinePlus Pages: Arrhythmia, Drug Reactions, Hepatitis C (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 25, 2015 Category: Consumer Health News Source Type: news
Hepatitis C Treatments Containing Sofosbuvir in Combination With Another Direct Acting Antiviral Drug: Drug Safety Communication - Serious Slowing of Heart Rate When Used With Antiarrhythmic Drug Amiodarone
Postmarketing cases of serious and life-threatening symptomatic bradycardia, as well as one fatal cardiac arrest and cases requiring pacemaker insertion, have been reported. (Source: FDA MedWatch)
Source: FDA MedWatch - March 24, 2015 Category: American Health Source Type: news
Gilead stock drops on hepatitis C drug's heart warning
Gilead Sciences Inc., which warned doctors and other health-care providers late last week not to use its groundbreaking hepatitis C drugs with patients on a well-known heart medication, saw its stock drop 2 percent in trading Monday.
The Foster City-based drug developer (NASDAQ: GILD) said one patient taking its drugs Harvoni or Sovaldi as well as the heart drug amiodarone died of cardiac arrest and three required a pacemaker. In all, the company said, nine patients developed abnormally slow heartbeats.
Amiodarone,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 24, 2015 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
FDA: Bradycardia Risk With Amiodarone Plus Hep-C AntiviralsFDA: Bradycardia Risk With Amiodarone Plus Hep-C Antivirals
The FDA is updating labeling for Harvoni and Savoldi antivirals after the death of one patient, and pacemaker implantation in three others, who were also on the antiarrhythmic agent. News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 23, 2015 Category: Cardiology Tags: Cardiology News Alert Source Type: news
